Table 3.
Comparison of antimicrobial regimens in hospitalized elderly CAP patients with clinical failure and clinical success (n = 3011)
| Regimen | CF(n = 395) | CS(n = 2616) | p value |
|---|---|---|---|
| Consistent with guideline | 115 (29.1) | 1032 (39.4) | <0.001 |
| β-lactam | 76 (19.2) | 579 (22.1) | |
| Fluoroquinolone | 22 (5.6) | 368 (14.1) | |
| β-lactam + macrolide | 6 (1.5) | 74 (2.8) | |
| β-lactam + fluoroquinolone | 22 (5.6) | 11 (0.4) | |
| Undertreated by guideline | 138 (34.9) | 396 (15.1) | <0.001 |
| β-lactam | 99 (25.1) | 302 (11.5) | |
| β-lactam + macrolide | 8 (2.0) | 42 (1.6) | |
| Macrolide | 1 (0.3) | 18 (0.7) | |
| Fluoroquinolone +/− β-lactam/other | 18 (4.6) | 17 (0.6) | |
| Other combination | 12 (3.0) | 17 (0.6) | |
| Overtreated by guideline | 142 (35.9) | 1188 (45.4) | <0.001 |
| Antipseudomonal β-lactam | 47 (11.9) | 468 (17.9) | |
| Fluoroquinolone +β-lactam/ other | 71 (18.0) | 585 (22.4) | |
| Antipseudomonal β-lactam+ macrolide | 6 (1.5) | 45 (1.7) | |
| Antipseudomonal β-lactam + other | 11 (2.8) | 52 (2.0) | |
| Fluoroquinolone + macrolide | 0 (0) | 17 (0.6) | |
| β-lactam +quinolone+ other | 5 (1.3) | 11 (0.4) | |
| β-lactam +macrolide+ fluoroquinolone /other | 2 (0.5) | 10 (0.4) |
Note: other = imidazoles, lincomycin, etracyclines, aminoglycoside, fosfomycin, glycopeptides and antifungal agents